New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
09:37 EDTTCK, IRG, PLD, THOR, PNG, IT, CFN, NUAN, OSK, CYS, SKUL, DE, BG, RVBD, ITW, CMI, TEVA, ANROn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Alpha Natural (ANR) downgraded to Fair Value from Buy at CRT Capital... Riverbed (RVBD) downgraded to Market Perform from Outperform at FBR Capital... Skullcandy (SKUL) downgraded to Neutral from Buy at Roth Capital... Teva (TEVA) downgraded to Hold from Buy at Canaccord... Bunge (BG) downgraded to Hold from Strong Buy at Feltl... CYS Investments (CYS) downgraded to Neutral from Buy at Compass Point... Deere (DE) downgraded to Buy from Strong Buy at ISI Group... Cummins (CMI) downgraded to Buy from Strong Buy at ISI Group.. Oshkosh (OSK) downgraded to Buy from Strong Buy at ISI Group... Illinois Tool Works (ITW) downgraded to Buy from Strong Buy at ISI Group... Gartner (IT) downgraded to Neutral from Overweight at Piper Jaffray... ProLogis (PLD) downgraded to Hold from Buy at Stifel Nicolaus... Nuance (NUAN) downgraded to Hold from Buy at Stifel Nicolaus... CYS Investments (CYS) downgraded to Hold from Buy at Stifel Nicolaus... PAA Natural Gas Storage (PNG) downgraded to Market Perform from Outperform at Raymond James... Ignite Restaurant (IRG) downgraded to Outperform from Strong Buy at Raymond James... CareFusion (CFN) downgraded to Outperform from Buy at CLSA... Riverbed (RVBD) downgraded to Neutral from Buy at Lazard Capital... Thoratec (THOR) downgraded to Market Perform from Outperform at Northland Securities... Teck Resources (TCK) downgraded to Neutral from Overweight at JPMorgan.
News For ANR;RVBD;SKUL;TEVA;BG;CYS;CMI;DE;OSK;ITW;IT;PLD;NUAN;PNG;IRG;CFN;THOR;TCK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
July 21, 2015
16:09 EDTNUANNuance sees Q3 EPS 31c-32c, consensus 28c
Sees Q3 revenue $485M-$489M, consensus $477M. On May 7, 2015, Nuance provided initial guidance for Q3 of $468M-$482M in revenue and 25c-29c in EPS.
15:08 EDTTHORThoratec reaches all-time high after report of St. Jude takeover
Subscribe for More Information
15:02 EDTITWNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Coca-Cola (KO), consensus 60c... Boeing (BA), consensus $1.42... Abbott Laboratories (ABT), consensus 50c... Thermo Fisher Scientific (TMO), consensus $1.78... EMC (EMC), consensus 41c... Illinois Tool Works (ITW), consensus $1.28... St. Jude Medical (STJ), consensus $1.00... Northern Trust (NTRS), consensus 96c... Check Point Software (CHKP), consensus 95c... Polaris Industries (PII), consensus $1.58... Interpublic Group (IPG), consensus 27c... New York Community Bancorp (NYCB), consensus 26c... B/E Aerospace (BEAV), consensus 76c... Owens Corning (OC), consensus 54c... Knight Transportation (KNX), consensus 37c.
14:52 EDTTHORThoratec could possibly get $65-$70 per share in takeover, says Northland
Subscribe for More Information
13:56 EDTTHORSt. Jude Medical bid for Thoratec makes strategic sense, says JPMorgan
Subscribe for More Information
12:40 EDTTHORSt. Jude in talks to acquire Thoratec, Bloomberg reports
St. Jude Medical (STJ) is in talks to acquire Thoratec (THOR), Bloomberg reports, citing people familiar with the situation. Talks are ongoing and could still fall apart as no deal has been reached, Bloomberg adds. Thoratec shares spiked early in today's session, but a catalyst for the move was unclear before the Bloomberg report. Shares of the medical device maker focused on advanced heart failure patients are up $9.52 to $58.33 in midday trading. Its close competitor HeartWare (HTWR) is now up $5.53 to $84.70. Shares of St. Jude are up 4 to $76.61. Reference Link
12:33 EDTTHORThoratec jumps after Bloomberg report of St. Jude buyout talks
Subscribe for More Information
12:29 EDTTHORSt. Jude Medical in talks to acquire Thoratec, Bloomberg reports
Subscribe for More Information
12:21 EDTTHOROn The Fly: Top stock stories at midday
Subscribe for More Information
10:20 EDTTHORCatalyst behind Thoratec spike higher unclear
The catalyst behind the spike higher in shares of Thoratec (THOR) is unclear to traders and investors. The medical device maker focused on advanced heart failure patients rose as high $62.05 in early trading and its shares remain up 11%, or $5.48, to $54.29. Some vague takeover chatter surfaced, with St. Jude Medical (STJ) as the speculated buyer, but buyout rumors are often the "go-to" reason when stocks spike. Often the moves on rumors are less substantial than Thoratec's spike today. The company's close competitor HeartWare (HTWR) is not seeing any unusual trading thus far today, falling 36c to $78.81 in early trading.
10:14 EDTTHORHigh option volume stocks:
Subscribe for More Information
10:12 EDTTHORThoratec calls active on sharp rally
Thoratec August 55 and 65 calls are active on 260 contracts (50 puts). August call option implied volatility is at 55, September is at 50; compared to its 52-week range of 24 to 51. Active calls suggests traders taking positions for price movement.
09:58 EDTTHORThoratec jumps 14% to $55.82 in early trading
Subscribe for More Information
08:04 EDTPLDPrologis raises FY15 core FFO to $2.18-$2.22 from $2.16-$2.22
Subscribe for More Information
08:04 EDTPLDPrologis increases annual dividend by 11% to $1.60
Subscribe for More Information
08:03 EDTPLDPrologis reports Q2 core FFO 52c vs. 48c last year
Subscribe for More Information
July 20, 2015
14:28 EDTPLDPrologis technical remarks ahead of earnings news
Subscribe for More Information
10:26 EDTTEVALeerink's specialty pharma/generics analyst has analyst/industry conference call
Specialty Pharmaceuticals / Generics Analyst Gerberry, along with MEDACorp Specialists Michael Belliveau, PhD and Shashank Upadhye, JD, discuss the strengths and weaknesses of TEVA's preliminary responses to the IPR challenge on Copaxone 40mg, the likely outcomes for the Copaxone 40mg patent challenge and perspectives on recent updates in the JAZZ Xyrem patent case on an Analyst/Industry conference call to be held on July 22 at 2 pm.
10:00 EDTANROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:48 EDTANRAlpha Natural downgraded to Neutral from Buy at Sterne Agee CRT
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use